SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Correction -Board Appointment

4 Apr 2008 17:04

Tristel PLC04 April 2008 Tristel plc ("Tristel" or "the Company") This announcement replaces RNS number 4433R Mr Green is currently interested in 909,016 Ordinary 1p Shares, representing3.4% per cent. of the Company's issued share capital. This replaces paragraphthree of the statement. Further to this, it should also be noted that TobyBrown Limited, Browns Cosmetics Limited, Browns Haircare Limited are previousappointments, not current appointments. Board Appointment Tristel plc, the AIM listed provider of infection and contamination controlproducts, announces the appointment of Mr Bruce Green as a non-executivedirector to the Board with immediate effect. Mr Green, aged 63, has acted as a consultant to Tristel since the incorporationof the Company in 1993. He is the original inventor/pioneer of Tristel'sproprietary chlorine dioxide technology and signed over the patents to Tristelat its admission to AIM in June 2005. Mr Green is currently interested in 864,016 Ordinary 1p Shares, representing 3.2per cent. of the Company's issued share capital. Mr Green is a Chartered Scientist, a Chartered Chemist and a member of the RoyalSociety of Chemistry. For the last 25 years Mr Green has acted as an independentconsultant and formulator in the infection control, cosmetics and food hygieneindustries. Pursuant to Rule 17, Schedule Two (g) of the AIM Rules for Companies thefollowing information is disclosed: Current Appointments Bruce Green Limited Food Safe Sales Limited Food Safe Limited (dormant) Floraceuticals Limited (dormant) Toby Brown Limited Browns Cosmetics Limited Browns Haircare Limited Previous Appointments Hairology Limited Claremont & May of Canterbury Limited Boxercise Limited Rugby Polo Club Limited Manufacturing Packaging Services Limited Health and Hygiene International Limited Formulas To Go Limited First Rung Housing Aqua Safe Technology Limited The Real Soil Associates Limited Mr Green was a Director of Janda Chemicals Limited at the time of itsliquidation, following the non payment of monies due from a creditor to JandaChemicals Limited. There is no further information to disclose. Tristel plc Paul Swinney, Chief Executive Tel: 01638 721 500 Daniel Stewart & Company PlcGraham Webster Tel: 020 7776 6576 Parkgreen Communications Ltd Tel: 020 7851 7480Lucy Lake Mob: 07894 263 046 lucy.lake@parkgreenmedia.com Notes to Editors Tristel's core business is the marketing of its proprietary chlorine dioxidechemistry that is highly effective in destroying all types of bacteria(including C difficile, MRSA, bacterial spores, and tuberculosis), fungi andviruses and is one of a small group of sporicidal agents that is safe and easyto use. Tristel plc operates with two divisions, Tristel Solutions and TristelTechnologies. Tristel Solutions focuses on infection control products for NHS and privatesector hospitals, primary care trusts, community hospitals, private practices,dental practices and veterinary establishments. The Company's products are usedon instruments, surfaces, and the skin in over 375 UK hospitals, representingsome 60 per cent of all UK NHS Acute & Private Hospitals. Tristel Technologies provides products for Legionella infection control inbuilding water systems and for contamination control in the food growing andfood processing industries. Tristel Technologies has approximately 200 customersin the government, municipal, industrial, healthcare and food sectors and more40 UK hospitals where its products are used for Legionella control. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding
5th Apr 20222:45 pmRNSDirector/PDMR Shareholding
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.